Skip to content
Mobidiag
Mobidiag
Enabling faster, more accessible molecular diagnostics
  • Home
  • Solutions
    • Respiratory Infections
    • Gastrointestinal Infections
    • Antimicrobial Resistance Management
    • Healthcare Associated Infections
    • Sepsis
  • Products
    • Coronavirus tests
    • Coronavirus solution
    • Amplidiag® RESP-4
    • Novodiag® COVID-19
    • Amplidiag® COVID-19
    • Mobidiag - Novodiag
    • Novodiag® Solution (CE-IVD)
    • COVID-19
    • C. difficile
    • Bacterial GE+
    • CarbaR+
    • Stool Parasites
    • Mobidiag - Amplidiag
    • Amplidiag® Solution (CE-IVD)
    • Amplidiag Easy
    • RESP-4
    • COVID-19
    • H. pylori+ClariR
    • Bacterial GE
    • CarbaR+VRE
    • CarbaR+MCR
    • Stool Parasites
    • Viral GE
    • C. difficile+027
    • LifeSciences (RUO)
    • S7 Fusion Polymerase™
    • Amplidiag® Multiplex PCR Master Mix
  • News
    • Corporate News
    • In the News
    • Events
    • Blog
  • Literature
    • Publications
    • Posters
    • Presentations
  • Company
    • About Us
    • Quality
    • Management Team
    • Investors
    • Careers
  • Contact
    • Contact Us
  • Log in
  • Log in

Corporate News

RICAI 2018, Paris, France

RICAI_logo
December 22, 2018

P. Bogaerts, W. Bouchahrouf, T-D Huang et Y. Glupczynski; Evaluation of Amplidiag CarbaR+MCR on clinical isolates.

Learn more about Amplidiag® CarbaR+MCR.

Share on: Share on FacebookShare on LinkedinShare on Twitter
Posted in: Posters

Post navigation

← RICAI 2018, Paris, France
NEW! Novodiag® CarbaR+, molecular diagnostic test for rapid and cost-effective detection for ‘superbacteria’ and associated drug resistance →

Mobidiag Logo

Mobidiag (HQ)

Keilaranta 16 A
FIN-02150 Espoo
Finland

+358 10 5050 770
sales@mobidiag.com

Mobidiag France

172 rue de Charonne
Le Dorian B2
75011 Paris
France

+33 1 55 25 17 00
adv@mobidiag.com

Mobidiag UK

Herschel House, 58 Herschel Street,
Slough, Berkshire, SL1 1PG,
UK
+44 (0) 333 305 7506
sales@mobidiag.com

Mobidiag Sweden

+358 10 5050 770
sales@mobidiag.com

Site map

  • Home
  • Solutions
    • Respiratory Infections
    • Gastrointestinal Infections
    • Antimicrobial Resistance Management
    • Healthcare Associated Infections
    • Sepsis
  • Products
    • Coronavirus solutions
    • Novodiag® Solution (CE-IVD)
      • COVID-19
        • Novodiag COVID-19
        • Amplidiag COVID-19
      • C. difficile
      • Bacterial GE+
      • CarbaR+
      • Stool Parasites
    • Amplidiag® Solution (CE-IVD)
      • COVID-19
      • H. pylori+ClariR
      • Viral GE
      • CarbaR+VRE
      • CarbaR+MCR
      • Stool Parasites
      • Bacterial GE
      • C. difficile+027
    • LifeSciences (RUO)
      • S7 Fusion Polymerase
      • Amplidiag® Multiplex PCR Master Mix
  • Corporate News
    • Corporate News
    • Events
    • Blog
  • Company
    • About Us
    • Quality
    • Management Team
    • Investors
    • Careers
  • Literature
  • Contact
    • Contact Us
  • Client Portal
    • Login or Register
    • Edit My Profile
  • Cookie Policy (EU)

Search

Contact Us

    • Home
    • Solutions
    • Products
    • Corporate News
    • Company
    • Literature
    • Contact
    • Client Portal
    • Cookie Policy (EU)
    • Linkedin
    • Twitter
    • Facebook
    Copyright © Mobidiag Ltd. All Rights Reserved.
    Mobidiag, Novodiag®, Amplidiag® and mNAT® are trademarks or registered trademarks of Mobidiag Oy. Other trademarks mentioned on this website
    are the property of their respective owners. No rights to use any trademarks or logos are granted    .
    Learn more about our Privacy policy.
    Website crafted by Design Reform.
    Top